文献速递临床试验与 GCP流行病学与生物统计

口服葡萄糖凝胶预防新生儿低血糖的多中心双盲随机对照试验

Evaluation of oral dextrose gel for prevention of neonatal hypoglycemia (hPOD): A multicenter, double-blind randomized controlled trial.
PubMed 文献 · PLoS Med · 2021-01-28

该研究在新西兰和澳大利亚18家医院纳入2149名有低血糖风险的新生儿,随机给予0.5 ml/kg颊部40%葡萄糖凝胶或安慰剂。预防性使用葡萄糖凝胶未降低NICU入住率(10.4% vs 9.4%,aRR 1.10),但降低了低血糖发生率(37% vs 42%,aRR 0.88)。

要点

  • 预防性葡萄糖凝胶未减少有低血糖风险新生儿的NICU入住。
  • 葡萄糖凝胶使低血糖发生率从42%降至37%(aRR 0.88)。
  • 两组因低血糖入住NICU的比例无显著差异。

核心结论

  • 预防性使用200 mg/kg葡萄糖凝胶未降低有低血糖风险新生儿的NICU入住率,但降低了低血糖发生率。
  • 需要长期随访以确定该策略的临床效用。

研究设计与样本

  • 多中心、双盲、安慰剂对照随机试验,于2015年1月至2019年5月在18家新西兰和澳大利亚产科医院进行。
  • 共随机2149名有低血糖风险(母亲糖尿病、晚期早产或高/低出生体重)且无NICU入住指征的新生儿,48.7%为女孩。
  • 干预为出生1小时时颊部给予0.5 ml/kg 40%葡萄糖凝胶或安慰剂凝胶。
  • 主要结局为NICU入住,检验4%绝对降低的效能。

主要发现

  • NICU入住率:葡萄糖凝胶组111/1070(10.4%),安慰剂组100/1063(9.4%)(aRR 1.10;95% CI 0.86, 1.42;p = 0.44)。
  • 低血糖(血糖<2.6 mmol/l)发生率:葡萄糖凝胶组399/1070(37%),安慰剂组448/1063(42%)(aRR 0.88;95% CI 0.80, 0.98;p = 0.02)。
  • 因低血糖入住NICU:葡萄糖凝胶组65/1070(6.1%),安慰剂组48/1063(4.5%)(aRR 1.35;95% CI 0.94, 1.94;p = 0.10)。
  • 出院时母乳喂养(aRR 1.00;95% CI 0.99, 1.02;p = 0.67)、出院前配方奶喂养(aRR 0.99;95% CI 0.92, 1.08;p = 0.90)、6周时配方奶喂养(aRR 1.01;95% CI 0.93, 1.10;p = 0.81)两组无差异,且无高血糖发生。
  • 95%的母亲愿意向朋友推荐该研究;无归因于葡萄糖凝胶的不良反应,每组各有2例死亡。

临床怎么用

  • 预防性葡萄糖凝胶可考虑用于降低有低血糖风险新生儿的低血糖发生率,但不应期望减少NICU入住。
  • 临床决策需结合长期随访结果进一步明确该策略的获益。

局限性

  • 81%的参与者为糖尿病母亲婴儿,可能限制普适性。
  • 16.5%的血糖测量使用了可靠性较低的分析仪。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neonatal hypoglycemia is common and can cause brain injury. Buccal dextrose gel is effective for treatment of neonatal hypoglycemia, and when used for prevention may reduce the incidence of hypoglycemia in babies at risk, but its clinical utility remains uncertain. METHODS AND FINDINGS: We conducted a multicenter, double-blinded, placebo-controlled randomized trial in 18 New Zealand and Australian maternity hospitals from January 2015 to May 2019. Babies at risk of neonatal hypoglycemia (maternal diabetes, late preterm, or high or low birthweight) without indications for neonatal intensive care unit (NICU) admission were randomized to 0.5 ml/kg buccal 40% dextrose or placebo gel at 1 hour of age. Primary outcome was NICU admission, with power to detect a 4% absolute reduction. Secondary outcomes included hypoglycemia, NICU admission for hypoglycemia, hyperglycemia, breastfeeding at discharge, formula feeding at 6 weeks, and maternal satisfaction. Families and clinical and study staff were unaware of treatment allocation. A total of 2,149 babies were randomized (48.7% girls). NICU admission occurred for 111/1,070 (10.4%) randomized to dextrose gel and 100/1,063 (9.4%) randomized to placebo (adjusted relative risk [aRR] 1.10; 95% CI 0.86, 1.42; p = 0.44). Babies randomized to dextrose gel were less likely to become hypoglycemic (blood glucose < 2.6 mmol/l) (399/1,070, 37%, versus 448/1,063, 42%; aRR 0.88; 95% CI 0.80, 0.98; p = 0.02) although NICU admission for hypoglycemia was similar between groups (65/1,070, 6.1%, versus 48/1,063, 4.5%; aRR 1.35; 95% CI 0.94, 1.94; p = 0.10). There were no differences between groups in breastfeeding at discharge from hospital (aRR 1.00; 95% CI 0.99, 1.02; p = 0.67), receipt of formula before discharge (aRR 0.99; 95% CI 0.92, 1.08; p = 0.90), and formula feeding at 6 weeks (aRR 1.01; 95% CI 0.93, 1.10; p = 0.81), and there was no hyperglycemia. Most mothers (95%) would recommend the study to friends. No adverse effects, including 2 deaths in each group, were attributable to dextrose gel. Limitations of this study included that most participants (81%) were infants of mothers with diabetes, which may limit generalizability, and a less reliable analyzer was used in 16.5% of glucose measurements. CONCLUSIONS: In this placebo-controlled randomized trial, prophylactic dextrose gel 200 mg/kg did not reduce NICU admission in babies at risk of hypoglycemia but did reduce hypoglycemia. Long-term follow-up is needed to determine the clinical utility of this strategy. TRIAL REGISTRATION: ACTRN 12614001263684.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Harding JE, Hegarty JE, Crowther CA, et al. Evaluation of oral dextrose gel for prevention of neonatal hypoglycemia (hPOD): A multicenter, double-blind randomized controlled trial. PLoS Med. 2021. PMID: 33507929. doi:10.1371/journal.pmed.1003411

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。